Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.